The goal of our studies is to improve disease-free and overall survival in subsets of patients with malignant lymphoma and Hodgkin's disease through the use of high dose therapy and stem cell grafting. The clinical studies proposed for years 04-08 will test 1) the relative efficacy and toxicity of high dose etoposide-containing preparative regimens in poor risk Hodgkin's disease, 2) the curative potential of high dose etoposide preparative regimens in recurrent intermediate and high grade lymphoma and the ability of post-transplant active immunotherapy to further decrease the rate of lymphoma relapse as assessed in a prospective randomized trial, and 3) the ability of consolidative high dose radiochemotherapy to prolong remission duration in advanced stage low grade lymphoma. In order to confirm the validity of our results in the phase II studies, we will employ a case- control statistical analysis in which therapeutic outcome will be compared to individually matched clusters of historical controls obtained from the Stanford Lymphoma Databank. Our studies incorporate novel methods to approach the problem of post- transplant relapse, which is the greatest obstacle to the successful use of ablative therapy and stem cell transplant in malignant lymphomas. Idiotype vaccination, which has been developed and studied by investigators in this Program Project, will be employed in a minimal disease state post- transplant in B-cell lymphoma patients. A novel method of fractionation of allogeneic bone marrow which results in a graft-versus-lymphoma effect, without graft-versus-host disease, has been developed by investigators in Project IV, and this approach will be studied in a clinical trial during the years 05-08. A clinical trial using highly purified stem cell preparations obtained through positive stem cell selection represents an approach to reduce relapse related to contamination of the marrow graft (see: Project IV). In addition, we will evaluate methods of detection of minimal residual disease, developed by investigators in the Program Project (see: Project III).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049605-08
Application #
5207559
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
1996
Total Cost
Indirect Cost
Zerboni, Leigh; Sung, Phillip; Sommer, Marvin et al. (2018) The C-terminus of varicella-zoster virus glycoprotein M contains trafficking motifs that mediate skin virulence in the SCID-human model of VZV pathogenesis. Virology 523:110-120
Muffly, Lori; Sheehan, Kevin; Armstrong, Randall et al. (2018) Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Adv 2:681-690
Tavallaee, Mahkam; Steiner, David F; Zehnder, James L et al. (2018) Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. Int J Gynecol Pathol :
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
Spinner, Michael A; Fernández-Viña, Marcelo; Creary, Lisa E et al. (2017) HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Adv 1:1347-1357
Costa, Helio A; Neal, Joel W; Bustamante, Carlos D et al. (2017) Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Mol Diagn Ther 21:431-436
Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634
Xu, Liwen; You, Xiaoqing; Zheng, PingPing et al. (2017) Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use. J Mol Diagn 19:72-83
Pierini, Antonio; Alvarez, Maite; Negrin, Robert S (2016) NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment. Stem Cells Int 2016:9025835
Nybakken, Grant E; Bala, Rajeev; Gratzinger, Dita et al. (2016) Isolated Follicles Enriched for Centroblasts and Lacking t(14;18)/BCL2 in Lymphoid Tissue: Diagnostic and Clinical Implications. PLoS One 11:e0151735

Showing the most recent 10 out of 307 publications